Haloperidol in Emotionally Disturbed Mentally Retarded Individuals
Abstract
The authors report a clinical study of the efficacy of a butyrophenone derivative (haloperidol) in a sample of mentally retarded children with associated emotional disturbances. The drug was noted to significantly alter the major target symptoms of such emotional disturbances. It appears that haloperidol is a welcome addition to the slowly growing armamentarium of effective psychopharmacological agents for the emotionally disturbed mentally retarded.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
